← Leaderboards
Jan Krumsiek
Weill Medical Coll Of Cornell Univ
$1,660,939
Attributed
$3,152,377
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $718K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,152,377 · 2
By mechanism
R01$2,982,877 · 1
R03$169,500 · 1
Top collaborators
- Matthias Arnold5 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Michael Joseph Satlin$3,693,103
- Nasser Khaled Altorki$2,970,612
- Vivek Mittal$10,850,597
- Olivier Elemento$10,592,678
- Alain C Borczuk$997,395
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposFutureClinical TrialsAffectMultidisciplinaryMetabolic PathwayIn SilicoMetabolomicsPathway InteractionsTissuesDrug CombinationsPharmaceutical PreparationsMolecularDrug CandidatePharmacotherapyAlgorithmsLinkAttentionAging PopulationBiological SystemsBiomedical ResearchBiological MarkersAnimal ModelCandidate Identification
Grant awards (7)
ADMINISTRATIVE SUPPLEMENT - TargetAD: A systems multi-omics approach to drug repositioning in Alzheimer's disease$388,842
R01 · FY2025 · AG · contact PI
TargetAD: A systems multi-omics approach to drug repositioning in Alzheimer's disease$684,233
R01 · FY2024 · AG · contact PI
TargetAD: A systems multi-omics approach to drug repositioning in Alzheimer's disease$717,961
R01 · FY2023 · AG · contact PI
TargetAD: A systems multi-omics approach to drug repositioning in Alzheimer's disease$566,897
R01 · FY2022 · AG · contact PI
Rational design of drug combinations to target chemotherapy resistance in high-grade serous ovarian cancer via metabolomic profiling of patient-derived organoids$84,750
R03 · FY2022 · CA · contact PI
TargetAD: A systems multi-omics approach to drug repositioning in Alzheimer's disease$624,944
R01 · FY2021 · AG · contact PI
Rational design of drug combinations to target chemotherapy resistance in high-grade serous ovarian cancer via metabolomic profiling of patient-derived organoids$84,750
R03 · FY2021 · CA · contact PI